

Figure S1. Schematic diagram of the phenylalanine metabolic pathway.




Figure S2. Daily assessment of clinical PASI scores in imiquimod-induced psoriasis-like mice fed with different doses of phenylalanine. (A) Daily scoring of skin thickness. (B) Daily scoring of scaling. (C) Daily scoring of erythema. (D) Total PASI scores over the 6-day period. Statistical significance was determined using two-way ANOVA, followed by Tukey's multiple comparisons test. * $P < 0.05$. ns, not significant; PASI, Psoriasis Area and Severity Index.




Figure S3. Daily assessment of clinical PASI scores following JPH203 treatment in IMQ-induced psoriasis-like mice. (A) Daily scoring of skin thickness. (B) Daily scoring of scaling. (C) Daily scoring of erythema. (D) Total PASI scores over the 6-day period. Statistical significance was determined using two-way ANOVA, followed by Tukey's multiple comparisons test. * $P < 0.05$. ns, not significant; PASI, Psoriasis Area and Severity Index; NC, normal control; IMQ, imiquimod.

